aMoon is a fusion of life science specialists, hi-tech pioneers and private-public experts who are passionate about actualizing Israel’s potential to challenge global healthcare.

The team's international ventures background and unique interdisciplinary skills are key factors in building effective collaboration within Israel's healthcare ecosystem. These relationships generate a vast network of exclusive opportunities and deal flow, providing deep value for our partners.

aMoon is a fusion of life science specialists, hi-tech pioneers and private-public experts who are passionate about actualizing Israel’s potential to challenge global healthcare.

The team's international ventures background and unique interdisciplinary skills are key factors in building effective collaboration within Israel's healthcare ecosystem. These relationships generate a vast network of exclusive opportunities and deal flow, providing deep value for our partners.

  • Dr. Yair Schindel, M.D.
    Co-Founder and Managing Partner

    Dr. Yair Schindel is the Managing Partner and co-founder of aMoon.

    Previously, Yair served as the founding CEO of the State of Israel’s National Digital Bureau, responsible for digitizing governmental services and stimulating economic growth.

    Yair is the founder of the MAOZ Network, an NGO building collaboration between Israel’s most influential leaders, with over 300 alumni dedicated to building collaboration between the private, social and public sectors.

    Yair was an executive, investor, board or advisory board member in several healthcare startups including OmniGuide, Zebra Medical Vision, and Medisafe.

    Yair earned his BSc and MD degrees at Ben-Gurion University and his MBA at Harvard Business School. He served in the IDF for five years and graduated as Chief Medical Officer for the Israeli Navy Seals, known as “Shayetet 13”.

  • Marius Nacht
    Anchor Investor

    Marius Nacht is a co-founder and partner at aMoon. In 1993, Marius co-founded Check Point Software Technologies Ltd. (NASDAQ:CHKP), a global pioneer of cybersecurity and the largest company in Israel. He is considered one of the founding fathers of Israel’s global cybersecurity industry.

    Marius holds a BSc, cum laude, in Physics and Mathematics, from Hebrew University, and an MSc in Electrical Engineering and Communications Systems from Tel Aviv University. He is a graduate of the IDF elite Talpiyot technological academy.

  • Isaac Devash

    Isaac Devash is a Partner at aMoon. After beginning his career as an M&A specialist in investment banking at Credit Suisse First Boston in NY, London and Tokyo, Isaac spent over 20 years in Venture Capital and Private Equity.

    In the last several years, he was senior advisor to Permira in the purchase of Netafim (bought for $850M, sold at $1.9B) and to XIO in the purchase of Lumenis for $512M. Previously, he managed the $156M Renaissance Fund and set up the $50M Israel Intl’ Fund. Isaac is a co-founder of Atodut Le'Israel, a national initiative of more than 15 talent management programs. He served as an active advisor to the Israeli government in numerous capacities such as The Committee for Corporate Governance, and a variety of committees that improved the allocation of capital for the private sector; the government and the public sector, while decreasing systemic risk. Isaac  is the founding Chairman of both the Wharton and Harvard Business School Clubs of Israel.

    Isaac serviced as an officer in the Artillery Corps of the IDF. He holds a Bachelors summa cum laude from Wharton and MBA from Harvard University.

  • Todd Sone

    Todd Sone is a partner at aMoon and has over fifteen years of healthcare investment experience. Prior to joining aMoon, he was a Managing Director at Signet Healthcare Partners, a NYC-based investment fund that provides growth capital to commercial stage life-science companies. Todd has served on the boards of Arbor Pharmaceuticals (Sold to KKR), Apicore (Sold to Medicure), Impopharma, and Smart Medical Systems. He also helped oversee the investment in Claris Lifesciences (sold to Baxter).

    Prior to joining Signet, Todd was an Investment Director at Joddes Limited, a family investment holding company with interests in a number of healthcare companies, including Pharmascience, Paladin Labs, Medicom, and Oral Science. He was previously a large-cap pharmaceutical analyst at Morgan Stanley. He started his career at Mercer Management Consulting serving clients across North America in the transportation and healthcare industries.

    Todd received a B.Com (with High Distinction) from the University of Toronto and an MBA from The Wharton School at the University of Pennsylvania with concentrations in healthcare management and finance.

  • Michal Goren Miller
    Vice President and General Counsel

    Michal Goren Miller is vice president and general counsel of aMoon. She was the former deputy CEO and Legal Chief of the National Digital Bureau in the Prime Minister’s Office, and was a member of both the Board of Directors and the Investment Committee at K.H.R. Study Funds, Ltd..

    Previously, Michal was Head of the Personal Banking Division at U-Bank Ltd., (responsible for managing branches, the investment advisory unit, business teams, operations, and current accounts) and member of the bank's Board of Directors. Additionally, Michal served as legal advisor at Bank Hapoalim’s Commercial Division, Special Credit Unit for 12 years.

    Michal earned her MSc in Management of Organizational Behavior Science at Tel Aviv University and holds a LLB and an LLM from Tel Aviv University.

  • Dr. Tomer Berkovitz, PhD
    Managing Director & CFO

    Dr. Tomer Berkovitz is a Managing Director & CFO at aMoon and has more than a decade of US capital markets experience. Prior to joining aMoon, he was the CFO & COO of Alcobra (NASDAQ: ADHD), a development-stage biotech company, where he led two successful public equity offerings from leading US healthcare funds for a total of more than $70 million. He also led Alcobra’s merger with Arcturus Therapeutics (NASDAQ: ARCT), a San-Diego based mRNA company. 

    Prior to joining Alcobra, he was an Executive Director in J.P. Morgan’s Investment Banking Division in New York, where he played a leading role in numerous capital market and mergers and acquisitions transactions. In this capacity, he advised senior management and boards of directors of J.P. Morgan's key U.S. clients, including several S&P 500 healthcare firms. Prior to joining J.P. Morgan, Tomer worked in Citigroup's Investment Bank in New York. From 2000 to 2003, he served as an economist in the Financial Advisory Unit to the Chief of Staff of the Israel Defense Forces.

    Tomer holds a Ph.D. in Finance and Economics (with Distinction) from Columbia Business School and has published a number of corporate finance articles in leading academic and practitioner journals. He also holds an M.Sc. in Finance and Accounting (Magna Cum Laude) and a B.A. in Economics and Management (Magna Cum Laude), both from Tel-Aviv University.

  • Roy Wiesner
    Managing Director & COO

    Roy Wiesner is Principal & COO at aMoon. He has nearly 15 years of investment experience, first as an M&A and Private Equity lawyer in New York, Hong Kong and Tel Aviv, and later as a venture capitalist.

    Before joining aMoon, Roy was the CEO of Hutchison Kinrot, a global leading incubator and seed investor in water technologies & Cleantech, owned by Hong Kong conglomerate CK Hutchison Holdings. He led numerous investments in early stage Israeli start-ups, serving on the boards of all portfolio companies and guiding them from technological concept to early commercialization. Prior to that he was a Partner at the International M&A and Capital Markets department of a leading Israeli law firm, also heading its private equity practice.

    Roy spent nearly five years with international law firm Weil Gotshal, working on complex M&A and Private Equity transactions, and was a member of the founding team of the firm's Hong Kong office.

    He holds an LLB from the Hebrew University of Jerusalem, and dual MPA (Public & Economic Policy) from the London School of Economics and Columbia University. He is a certified lawyer in Israel and New York.

  • Guy Spigelman
    Entrepreneur in Residence

    Guy Spigelman is an Entrepreneur in Residence at aMoon. Previously, Guy served as CEO of PresenTense – a network of start-up accelerators that launches over 100 startups per year. In this role, Guy founded 7 new accelerator programs, including A3i – the first accelerator in the world focused on Assistive and Aging

    Prior to PresenTense, Guy served as VP of Business Development at Apos, an aMoon portfolio company, where he was responsible for the establishment and management of subsidiaries in Europe and APAC.
    Before this role, Guy held various executive sales, marketing, business development and product positions
    at Israeli software companies, including XMPie that was acquired by Xerox and the NASDAQ listed Radview.

    Guy serves as a Major (reserves) in the IDF Spokesperson Unit, and was the Chairperson of Merchavim – an NGO promoting shared society at over 500 schools and kindergartens across Israel.

  • Dr. Yifat Segev, PhD
    Life-science Data Analyst

    Dr. Yifat Segev is a life-science data analyst at aMoon. She earned her PhD from the Department of Neurobiology at Haifa University, where she specialized in neuroscience, focusing on biochemical pathways of learning and memory in Alzheimer's disease. Her work ultimately led to a patent and a spinout company via the Carmel Ltd., Technology Transfer Organization.

    Yifat’s MSc is from the Weizmann Institute, where she specialized in Neuroimmunology. She earned her BSc from the Technion-Israel Institute of Technology, which included study at Carnegie Mellon University. She has published numerous scientific papers, including in Neurobiology of Aging and the Journal of Neuroscience, and she has been cited in a number of innovative papers.

  • Daniel E. Cohen
    Investment Analyst

    Daniel E. Cohen is an investment analyst at aMoon. Previously, he worked as an investment banker in New York, advising on mergers and acquisitions, equity and debt capital raising, and royalty monetizations in the healthcare industry. While at MTS Health Partners, Daniel closely served on the deal teams advising clients such as Otsuka Pharmaceutical, Horizon Pharma, and Caladrius Biosciences, for a total deal volume of ~$2 billion. He also worked as a senior analyst at Lazard Frères & Co., advising corporate clients on special situations, including a healthcare services company in an activist investor campaign.

    Daniel earned his BA in Financial Economics from Columbia University, where he focused on Biopharmaceutical Development & Regulation.

  • Dr. Moria Kwiat, PhD

    Dr. Moria Kwiat is an analyst at aMoon. Formerly, she was an analyst at Frost & Sullivan, leading their Israeli Health Care division. Moria is a board member at Pluristem Therapeutics Inc., and was a research associate in the Center for Nanoscience and Nanotechnology at Tel Aviv University. A specialist in the field of biotechnology with a strong track record of developing biosensors for diagnostics utilizing electrical devices, Moria co-authored 13 scientific papers.

    Moria holds a Ph.D. and Postdoc in Nano-Biotechnology from Tel Aviv University, and a M.Sc. Magna Cum Laude in Biotechnology from Tel Aviv University.

  • Tamir Maixner

    Tamir Maixner joined the aMoon fund as an intern in 2017. He is a Third-year student in an honor's program for an LLB in Law and MA in Financial Economics at the IDC, Hertzliya. Prior to aMoon Tamir worked as a student intern at the state's attorney Financial and Fiscal department. Tamir served as a captain in the Israeli navy seals, Shayetet 13, and continues to serve as such in reserve service.

  • Shiran Ella
    Executive Assistant

    Shiran Ella is the executive assistant to the managing partners at aMoon. She holds a BA and MA, in Political Science from the Hebrew University in Jerusalem. Shiran previously worked as the senior office manager at the government’s National Digital Bureau, of the Prime Minister's Office.